Uveal melanoma in the Iranian population: two decades of patient management in a tertiary eye center

Table 2 The characteristics of deceased patients with uveal melanoma

	Age at presentation	Gender	Symptoms	Initial BCVA	Final BCVA	Treatment	Time to death (months)	Cause of death	Presence of metastasis	Location of metastasis	Diameter (mm)	Thickness (mm)	Location of the lesion	Extraocular extension	Pathology	Pigmentation	Adjuvant therapy	Laterality
1	61	Male	Visual loss	1/10	-	Enucleation	21	Metastasis	Yes	Liver	18.96	11.19	Choroid	No	Mixed cell	Pigmented	Interferon alpha 2b	OS
2	70	Male	Visual loss	LP	-	Brachytherapy then enucleation	16	Metastasis	Yes	Liver	16.72	12.91	Ciliary body	No	Spindle B	Pigmented	-	OD
3	37	Female	Pain - swelling	NLP	-	Enucleation	38	Metastasis	Yes	Liver	13	8.2	Choroid adjacent to disc	No	Mixed (necrotic)	Pigmented	-	OD
4	60	Male	Visual loss	4/10	CF 1 m	Brachytherapy	35	Metastasis	Yes	Lung	9.03	3.21	Choroid	No	-	Pigmented	-	OD
5	21	Male	Metamorphopsia	3/10	CF 1 m	Brachytherapy	58	Metastasis	Yes	Liver	20.58	11.77	Choroid	No	-	Pigmented	TTT laser	OD
6	59	Female	Visual loss	3/10	LP	Brachytherapy	34	-	No	-	11.17	4.27	Choroid adjacent to disc	No	-	Pigmented	-	OS
7	82	Male	Visual loss	LP	-	Enucleation	26	-	No	-	14.32	16.87	Choroid	No	-	Pigmented	-	OS
8	71	Male	Visual loss	CF2m	CF1m	Brachytherapy	44	Metastasis	Yes	Liver	15	5.7	Choroid	No	-	Pigmented	-	OD

BCVA: Best corrected visual acuity, CF: Count finger, LP: Light perception, NLP: No Light perception

ISSN: 2056-9920